NIH Funds SIGA Dengue Antiviral Program Read more about NIH Funds SIGA Dengue Antiviral Program SIGA Technologies Awarded $55 Million by Federal Government to Develop Broader Applications for Its Lead Drug Candidate ST-246 Read more about SIGA Technologies Awarded $55 Million by Federal Government to Develop Broader Applications for Its Lead Drug Candidate ST-246 SIGA Receives $8 Million in Financing Support from MacAndrews & Forbes Read more about SIGA Receives $8 Million in Financing Support from MacAndrews & Forbes SIGA Advances Dengue Antiviral Program Read more about SIGA Advances Dengue Antiviral Program SIGA Adds Vice President of Clinical and Regulatory Affairs to Management Team Read more about SIGA Adds Vice President of Clinical and Regulatory Affairs to Management Team SIGA Begins Negotiations with Government Agency for Additional Funding to Accelerate ST-246 Commercial Scale Manufacturing Read more about SIGA Begins Negotiations with Government Agency for Additional Funding to Accelerate ST-246 Commercial Scale Manufacturing SIGA Initiates Manufacture of ST-246 NDA Registration Batches Read more about SIGA Initiates Manufacture of ST-246 NDA Registration Batches Dr. Dennis E. Hruby, Chief Science Officer of SIGA Technologies, to Present CDC Distinguished Lecture on Smallpox Antiviral Drug ST-246 Read more about Dr. Dennis E. Hruby, Chief Science Officer of SIGA Technologies, to Present CDC Distinguished Lecture on Smallpox Antiviral Drug ST-246 SIGA Advances ST-246 Smallpox Antiviral Development in Europe Read more about SIGA Advances ST-246 Smallpox Antiviral Development in Europe SIGA Successfully Completes ST-246 Multiple Ascending Dose Human Clinical Trial Read more about SIGA Successfully Completes ST-246 Multiple Ascending Dose Human Clinical Trial Pagination First page « First Previous page ‹ Previous … Page 21 Page 22 Page 23 Page 24 Current page 25 Page 26 Page 27 Page 28 Page 29 Next page Next › Last page Last » Subscribe to
SIGA Technologies Awarded $55 Million by Federal Government to Develop Broader Applications for Its Lead Drug Candidate ST-246 Read more about SIGA Technologies Awarded $55 Million by Federal Government to Develop Broader Applications for Its Lead Drug Candidate ST-246
SIGA Receives $8 Million in Financing Support from MacAndrews & Forbes Read more about SIGA Receives $8 Million in Financing Support from MacAndrews & Forbes
SIGA Adds Vice President of Clinical and Regulatory Affairs to Management Team Read more about SIGA Adds Vice President of Clinical and Regulatory Affairs to Management Team
SIGA Begins Negotiations with Government Agency for Additional Funding to Accelerate ST-246 Commercial Scale Manufacturing Read more about SIGA Begins Negotiations with Government Agency for Additional Funding to Accelerate ST-246 Commercial Scale Manufacturing
SIGA Initiates Manufacture of ST-246 NDA Registration Batches Read more about SIGA Initiates Manufacture of ST-246 NDA Registration Batches
Dr. Dennis E. Hruby, Chief Science Officer of SIGA Technologies, to Present CDC Distinguished Lecture on Smallpox Antiviral Drug ST-246 Read more about Dr. Dennis E. Hruby, Chief Science Officer of SIGA Technologies, to Present CDC Distinguished Lecture on Smallpox Antiviral Drug ST-246
SIGA Advances ST-246 Smallpox Antiviral Development in Europe Read more about SIGA Advances ST-246 Smallpox Antiviral Development in Europe
SIGA Successfully Completes ST-246 Multiple Ascending Dose Human Clinical Trial Read more about SIGA Successfully Completes ST-246 Multiple Ascending Dose Human Clinical Trial